|
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Clinical research trials and LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. clinical trial. Participants typically obtain the most effective healthcare available for their LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes. condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.  LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
For Condition: Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Non-Insulin-Dependent,Diabetic Neuropathies
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients must have type I or type II Diabetes Mellitus. - Have clinically diagnosed positive sensory symptoms such as numbness, lancinating pain, burning pain, aching pain, allodynia and prickling sensation that have been present not greater than 5 years but stable for 6 months. - Has a HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be insulin therapy. - Must be 18 years or older. - Be able to visit the doctor's office approximately 3 times over a maximum of a 6-week period to determine if you can continue in the study. Exclusion Criteria: - History of significant liver problems. - Have poor kidney function. - Drink an excess of alcohol or abuse drugs. - Have recently participated or currently participating in a Medical study in which you receive an experimental drug. - Are a woman and are pregnant or breastfeeding, intend to become pregnant within the next 2 years or a woman not using effective birth control.
Total Enrollment:
Location and Contact Information:
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Amersfoort, ,
Netherlands
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Baltimore, Maryland,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
New York City, New York,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Norwalk, Connecticut,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Klaipeda, ,
Lithuania
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Halifax, Nova Scotia,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Columbia, South Carolina,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Poole, Dorset,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Shrewsbury, Shropshire,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Zagreb, ,
Croatia
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Minneapolis, Minnesota,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
San Antonio, Texas,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Norwalk, Connecticut,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Laval, Quebec,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Boston, Massachusetts,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Vancouver, British Columbia,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Columbia, Missouri,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Salford, Manchester,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Kaunas, ,
Lithuania
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Clearwater, Florida,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Vilnus, ,
Lithuania
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Columbia, Missouri,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Idaho Falls, Idaho,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Manchester, ,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Toronto, Ontario,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
North Chicago, Illinois,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Sheffield, South Yorkshire,
United Kingdom
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Mumbai, Maharashtra,
India
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Oulu, ,
Finland
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Long Beach, California,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Plantation, Florida,
United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Gopalapuram, Chennai,
India
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Jyvaskyla, ,
Finland
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Hyderabad, ,
India
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Winnipeg, Manitoba,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Charlottetown, Prince Edward Island,
Canada
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Helsinki, ,
Finland
Additional Information:
Study ID Numbers: 6204;
Study Start Date: July 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00044408
Other Diabetic Neuropathies Studies:
1. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
2. Continuous Glucose Monitors for Children With Diabetes Mellitus
3. hOKT3gamma1 (Ala-ala) for the prevention of human islet allograft failure
4. Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
5. Continuous Glucose Monitoring in Children With Type 1 Diabetes Mellitus
Related Studies:
Other Diabetic Neuropathies Clinical Trials
Other Connecticut Clinical Trials
Other Norwalk Clinical Trials
LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
|
|
|
|
|
|
|
|
